P. Leccese

发表

Alveolar haemorrhage in ANCA-associated vasculitis: Long-term outcome and mortality predictors.

D. Roccatello, L. Dagna, M. Matucci Cerinic, 2020, Journal of autoimmunity.

Management of major organ involvement of Behçet’s syndrome: a systematic review for update of the EULAR recommendations

R. Moots, I. Olivieri, P. Sfikakis, 2018, Rheumatology.

Management of skin, mucosa and joint involvement of Behçet's syndrome: A systematic review for update of the EULAR recommendations for the management of Behçet's syndrome.

R. Moots, I. Olivieri, P. Sfikakis, 2019, Seminars in arthritis and rheumatism.

Red flags for appropriate referral to the gastroenterologist and the rheumatologist of patients with inflammatory bowel disease and spondyloarthritis

I. Olivieri, P. Gionchetti, A. Armuzzi, 2019, Clinical and experimental immunology.

Golimumab for the treatment of axial spondyloarthritis

I. Olivieri, S. D’Angelo, M. Gilio, 2017, Expert opinion on biological therapy.

Impact of the COVID-19 Pandemic on the Appropriateness of Diagnostic Pathways of Autoimmune Rheumatic Diseases

E. Esposito, S. D’Angelo, P. Leccese, 2021, The Journal of Rheumatology.

Risk of acute arterial and venous thromboembolic events in eosinophilic granulomatosis with polyangiitis (Churg–Strauss syndrome)

S. Kiechl, P. Willeit, J. Willeit, 2020, European Respiratory Journal.

Pharmacological therapy of spondyloarthritis

I. Olivieri, S. D’Angelo, M. Gilio, 2015, Expert opinion on pharmacotherapy.

Anti-TNF agents for the treatment of active non-radiographic axial spondyloarthritis.

I. Olivieri, S. D’Angelo, P. Leccese, 2013, Reumatismo.

Adalimumab for treatment of severe Behçet's uveitis: a retrospective long-term follow-up study.

I. Olivieri, E. Interlandi, P. Leccese, 2014, Clinical and experimental rheumatology.

2018 update of the EULAR recommendations for the management of Behçet’s syndrome

R. Moots, I. Olivieri, P. Sfikakis, 2018, Annals of the rheumatic diseases.

A First Step for the Molecular Characterization of Neurological Involvement of Behçet Syndrome: an Italian Pivotal Study

S. D’Angelo, M. Padula, P. Leccese, 2020, Journal of Molecular Neuroscience.

HLA-B*51 subtypes molecular analysis in a series of Italian patients with Behçet's syndrome.

M. Padula, P. Leccese, N. Lascaro, 2019, Joint, bone, spine : revue du rhumatisme.

New Insights into Behçet's Syndrome Metabolic Reprogramming: Citrate Pathway Dysregulation

P. Convertini, A. Santarsiero, V. Infantino, 2018, Mediators of inflammation.

Sensitivity of the Classification of Psoriatic Arthritis Criteria in Early Psoriatic Arthritis

I. Olivieri, P. Leccese, A. Padula, 2009, The Journal of Rheumatology.

Improvements in diagnostic tools for early detection of psoriatic arthritis

I. Olivieri, M. Gilio, P. Leccese, 2016, Expert review of clinical immunology.

An update on the management of hepatitis C virus-related arthritis

I. Olivieri, M. Gilio, P. Leccese, 2014, Expert opinion on pharmacotherapy.

AB0009 IDENTIFICATION OF A NOVEL POLYMORPHISM OF ERAP1 IN A GROUP OF ITALIAN PATIENTS WITH BEHçET SYNDROME

M. Padula, P. Leccese, A. Padula, 2019 .

Safety of anti-tumor necrosis factor agents in psoriatic arthritis – an update

I. Olivieri, P. Leccese, A. Padula, 2014, Expert opinion on drug safety.

Behçet’s Disease: An Overview of Etiopathogenesis

E. Alpsoy, P. Leccese, 2019, Front. Immunol..

Review of the treatment of psoriatic arthritis with biological agents: choice of drug for initial therapy and switch therapy for non-responders

I. Olivieri, M. Gilio, P. Leccese, 2017, Open access rheumatology : research and reviews.

Emerging drugs for psoriatic arthritis

I. Olivieri, E. Lubrano, P. Leccese, 2010, Expert opinion on emerging drugs.

Safety of treatment options for spondyloarthritis: a narrative review

F. Ursini, M. Gilio, P. Leccese, 2018, Expert opinion on drug safety.

Spondyloarthritis with Onset After Age 45

I. Olivieri, P. Leccese, A. Padula, 2013, Current Rheumatology Reports.

Can we reduce the dosage of biologics in spondyloarthritis?

I. Olivieri, P. Leccese, A. Padula, 2013, Autoimmunity reviews.

Standardization of red flags for referral to rheumatologists and ophthalmologists in patients with rheumatic diseases and ocular involvement: a consensus statement

I. Olivieri, P. Bisceglia, P. Neri, 2018, Rheumatology International.

Treatment of Behçet's Disease: An Algorithmic Multidisciplinary Approach

S. Ohno, E. Alpsoy, G. Emmi, 2021, Frontiers in Medicine.

Pure red aplasia induced by sodium valproate in a patient with Behçet's syndrome.

I. Olivieri, P. Leccese, A. Padula, 2017, Clinical and experimental rheumatology.

Efficacy of adalimumab in patients with Behçet's disease unsuccessfully treated with infliximab.

I. Olivieri, G. Coniglio, P. Leccese, 2011, Clinical and experimental rheumatology.

O 02-P 039 A comparative study about ERAP 1 polymorphisms in Behçet syndrome and ankylosing spondylitis Italian patients

N. Horita, A. Meguro, N. Mizuki, 2018 .

Long-Term Efficacy of Infliximab for Treatment of Severe Behçet's Uveitis

I. Olivieri, E. Interlandi, P. Leccese, 2015 .

Locomotor System Disease

S. Yurdakul, P. Leccese, 2019, Behçet Syndrome.

Genotyping of Italian patients with Behçet syndrome identified two novel ERAP1 polymorphisms using sequencing-based approach.

M. Gilio, M. Padula, P. Leccese, 2019, Human immunology.

Clinical phenotypes of Behçet’s syndrome in a large cohort of Italian patients: focus on gender differences

P. Leccese, N. Lascaro, S. d'Angelo, 2021, Scandinavian journal of rheumatology.

Behcet's syndrome in nonendemic regions

I. Olivieri, P. Leccese, Y. Yazici, 2017, Current opinion in rheumatology.

Successful treatment of recalcitrant genital ulcers of Behçet's disease with adalimumab after failure of infliximab and etanercept.

I. Olivieri, P. Leccese, A. Padula, 2009, Clinical and experimental rheumatology.

Correlation of Tumor Necrosis Factor-α -308G>A Polymorphism with Susceptibility, Clinical Manifestations, and Severity in Behçet Syndrome: Evidences from an Italian Genetic Case-Control Study.

R. Radice, M. Padula, P. Leccese, 2019, DNA and cell biology.

Identification of a de novo NLRP3 gene variation in an Italian Behçet syndrome patient

M. Padula, P. Leccese, A. Padula, 2019, International journal of immunogenetics.

Switching to adalimumab is effective in a case of neuro-Behcet's disease refractory to infliximab.

I. Olivieri, G. Coniglio, P. Leccese, 2010, Clinical and experimental rheumatology.

Successful treatment of leg ulcers in Behçet's disease using adalimumab plus methotrexate after the failure of infliximab.

I. Olivieri, P. Sarzi-Puttini, F. Atzeni, 2010, Clinical and Experimental Rheumatology.

High prevalence of Behçet's disease in southern Italy.

I. Olivieri, M. Gilio, P. Leccese, 2013, Clinical and experimental rheumatology.

Distribution of rs17482078 and rs27044 ERAP1 polymorphisms in a group of Italian Behçet’s syndrome patients: a preliminary case–control study

M. Gilio, M. Padula, P. Leccese, 2019, Internal and Emergency Medicine.

Efficacy of switching to adalimumab in a patient with refractory uveitis of Behçet's disease to infliximab.

I. Olivieri, P. Leccese, A. Padula, 2011, Clinical and experimental rheumatology.

Long-lasting Remission of Severe Behçet’s Disease After the End of Infliximab Therapy

I. Olivieri, P. Leccese, A. Padula, 2009, The Journal of Rheumatology.

Highlights of the 17 th International Conference on Behçet ’ s syndrome Matera , Italy , 15-17 September 2016

I. Olivieri, G. Hatemi, P. Leccese, 2016 .

Validity of Machine Learning in Predicting Giant Cell Arteritis Flare After Glucocorticoids Tapering

S. Tangaro, Claudia Fabiani, G. Emmi, 2022, Frontiers in Immunology.

The performance of CASPAR criteria in early psoriatic arthritis - preliminary results from an Italian prospective multicentric study

I. Olivieri, A. Mathieu, C. Salvarani, 2009 .

Late-Onset Spondyloarthritis: Subset That Should Not Be Forgotten

I. Olivieri, P. Leccese, A. Padula, 2012, The Journal of Rheumatology.

Empowering Patients in the Therapeutic Decision-Making Process: A Glance Into Behçet's Syndrome

D. Taruscio, A. Del Bianco, M. Mosca, 2021, Frontiers in Medicine.

Combination therapy with ciclosporin and etanercept in patients with psoriatic arthritis

I. Olivieri, E. Lubrano, P. Leccese, 2009, Annals of the rheumatic diseases.

AB0781 High Sensitivity of the ASAS Classification Criteria in Patients with HLA-B27 Positive Undifferentiated Spondyloarthritis with Onset of Disease After Age 45

I. Olivieri, M. Gilio, N. Akkoç, 2015 .

Vitamin D deficiency in systemic sclerosis: a possible role of subclinical liver fibrosis? Retrospective analysis from an Italian cohort

I. Olivieri, F. Ursini, G. Abignano, 2017, Clinical Rheumatology.

Real-world effectiveness of apremilast in multirefractory mucosal involvement of Behçet’s disease

Claudia Fabiani, G. Emmi, G. Lopalco, 2019, Annals of the rheumatic diseases.

Expert consensus on the treatment of patients with adult-onset still's disease with the goal of achieving an early and long-term remission.

L. Dagna, R. Caporali, R. Priori, 2023, Autoimmunity reviews.

Review of the treatment of psoriatic arthritis with biological agents: choice of drug for initial therapy and switch therapy for non-responders.

I. Olivieri, M. Gilio, P. Leccese, 2017, Open access rheumatology : research and reviews.

Review of the treatment of psoriatic arthritis with biological agents: choice of drug for initial therapy and switch therapy for non-responders

I. Olivieri, M. Gilio, P. Leccese, 2017 .

Worsening of psoriasis with rituximab therapy.

I. Olivieri, P. Leccese, D. Vertone, 2010, Clinical and experimental rheumatology.

Brain glucose consumption abnormalities in neuro-Behçet's disease: a preliminary 18F-FDG PET/CT study.

O. Schillaci, R. De Giorgio, A. Chiaravalloti, 2018, Clinical and Experimental Rheumatology.

Age at diagnosis influences the clinical phenotype, treatment strategies and outcomes in patients with giant cell arteritis: results from the observational GCAGE study on a large cohort of 1004 patients

A. Tomelleri, C. Campochiaro, L. Dagna, 2023, Annals of the Rheumatic Diseases.

Long-lasting Remission of Severe Behçet’s Disease After the End of Infliximab Therapy

I. Olivieri, L. Stamp, P. Leccese, 2009, The Journal of Rheumatology.

Review of the treatment of psoriatic arthritis with biological agents: choice of drug for initial therapy and switch therapy for non-responders

I. Olivieri, M. Gilio, P. Leccese, 2017, Open access rheumatology : research and reviews.

Vitamin D deficiency in systemic sclerosis: a possible role of subclinical liver fibrosis? Retrospective analysis from an Italian cohort

I. Olivieri, F. Ursini, G. Abignano, 2017, Clinical Rheumatology.

TNFα rs1800629 Polymorphism and Response to Anti-TNFα Treatment in Behçet Syndrome: Data from an Italian Cohort Study

M. Padula, P. Leccese, A. Padula, 2023, Journal of Personalized Medicine.

From structure to function for the characterization of ERAP1 active site in Behçet syndrome. A novel polymorphism associated with known gene variations.

M. Padula, P. Leccese, A. Padula, 2019, Molecular immunology.